Berger Montague Investigates Altimmune Securities Lawsuits

A class action lawsuit has been filed against Altimmune, a clinical-stage biopharmaceutical company, following the company's announcement of disappointing results from its IMPACT Phase 2b trial of Pemvidutide for the treatment of MASH. The trial's primary endpoint, fibrosis reduction, failed to achieve statistical significance, leading to a significant decline in Altimmune's stock price. Investors who purchased or acquired Altimmune securities between August 10, 2023, and June 25, 2025, may be eligible to seek compensation.

Key Takeaways:

Berger Montague is investigating claims under the federal securities laws against Altimmune, Inc.
A class action lawsuit was filed against Altimmune following the company's disappointing results from its IMPACT Phase 2b trial of Pemvidutide.
The trial's primary endpoint, fibrosis reduction, failed to achieve statistical significance.
Altimmune's stock price declined by more than 53% in a single day after the announcement.
Investors who purchased or acquired Altimmune securities between August 10, 2023, and June 25, 2025, may be eligible to seek compensation.
The lead plaintiff representative of the class must seek to be appointed by October 6, 2025.
Berger Montague has experience in securities class action litigation, representing individual and institutional investors for over five decades.

Statistics:

Decline in Altimmune's stock price: 53% in a single day.
Date range for eligible investors: August 10, 2023, to June 25, 2025.
Investor deadline to seek compensation: October 6, 2025.
Years of experience in securities class action litigation for Berger Montague: over 5 decades.

Sources:

Berger Montague PC investigation: August 22, 2025.
Class action lawsuit filing: Unspecified date, on or after August 10, 2023.
Altimmune press release: June 26, 2025.
Berger Montague: https://www.bergermontague.com/ (phone: 215-875-3015, e-mail: aabramowitz@bergermontague.com, or cadorni@bergermontague.com).